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Abstract-Postsynaptic a-receptor blocking properties of E-643 were studied in vivo and in vitro and compared with these same properties of phentolamine and phenoxy benzamine.
In anesthetized rats, E-643 (i.v.) attenuated pressor response to adre naline dose-dependently and an adrenaline-reversal was seen with large doses. The in vivo a-adrenoceptor blocking effect of E-643 was 3.4 times more potent than that of phentolamine.
On the other hand, hypotensive action of E-643 was 9.4 times more potent than that of phentolamine.
In the isolated rabbit aorta, E-643 blocked nor adrenaline-induced contraction of the aorta with a parallel shift of the dose-response curve to the right. The pA2 values for E-643 and phentolamine were 8.60 and 7.65, respectively. The a-blocking effect of E-643 was reversible. E-643 protected a receptors against irreversible inhibition by phenoxybenzamine.
E-643 neither exhibited significant blocking effects on K--, Bat and angiotensin-induced contractions of the aorta nor caused relaxation of the aorta contracted by Cat+. These data suggest that E-643 is a specific and competitive inhibitor of noradrenaline at the a-adrenoceptors. E-643 is one of the twenty-eight aminodimethoxyquinazoline derivatives which were synthesized and pharmacologically screened in our laboratories. In the course of the screening, E-643 was found to have potent activities in lowering blood pressure in anesthetized rats as well as antagonizing contractile response of the isolated rat vas deferens to /-noradrenaline (Noradr).
Long-lasting reduction in blood pressure in spontaneously hypertensive rats (SHR) and reversal of the pressor response to intravenously administered adrenaline in both nor motensive and hypertensive rats after an oral administration of E-643 were reported by Igarashi et al. (1, 2) . The hypotensive effect of E-643 in SHR was evident with oral doses over 0.1 mg/kg (2).
The experiments reported herein were a quantitative evaluation of the a-adrenoceptor blocking activity of E-643 in vivo and in vitro and clarification of the properties of the a-blocking action of E-643 was made.
MATERIALS AND METHODS
In vivo experiments: Normotensive male Sprague-Dawley rats weighing 390-500 g were anesthetized with urethane (1.5 g/kg, i.p. 
RESULTS
Effects on blood pressure and pressor response to Adr: Intravenous administration of a cumulative dose of E-643 or phentolamine produced a dose-dependent hypotension.
The fall in blood pressure caused by E-643 or phentolamine consisted of two phases; a transient fall followed by a persistent fall. Only the latter phase was taken for the calcu lation of ED20 mmHg. Figure 1 shows the relationship between the dose of E-643 or phentolamine and the resultant hypotensive response. E-643 and phentolamine exerted a maximum hypotensive effect in a dose of 300 and 3000 /-tg/kg, respectively. The extent of maximum hypotension of phentolamine was less than that of E-643 ( Fig. 1 ). The ED20 mmHg values for E-643 and phentolamine calculated from respective curves were 23.6±2.9
and 221.5±58.8 beg/kg, respectively. Significant difference was found between the two values (p<0.01). Thus, the hypotensive effect of E-643 was 9.4 times more potent than that of phentolamine. The concentration of adrenaline injected was 4 pg/mi. n Q: E-643, 0-10: Phentolamine. Insets are recordings of blood pressure response to adrenaline before (upper recording) and after (the lower recording) 300 ug/kg of E-643. Broken lines denote the level of mean blood pressure during the control period. Adrenaline was injected at the point indicated by the arrows. Note adrenaline reversal after the administration of E-643. Figure  2 shows the relationship between the dose of E-643 or phentolamine and the resultant inhibition of the pressor response to Adr (2 /cg/kg). Pressor response to Adr was dose-dependently attenuated by E-643 or phentolamine. Adrenaline-reversal was observed after an administration of E-643 in a large dose (Fig. 2) . ID50 values for E-643 and phentol amine calculated from respective curves were 6.38 -= 1.95 and 21.98-L6.02 tig/kg, respectively.
The difference between the two values was statistically significant (p<0.05). Thus, the a blocking effect of E-643 was 3.4 times more potent than that of phentolamine.
Effects on the cumulative dose-response curve to Noradr: 1-Noradrenaline was added to the bath in a volume of 20 cal with increasing concentration (final concentration: 1 x 10-s to 1 x 10-2 M), so that a cumulative dose-response curve was produced. E-643, phentolamine or phenoxybenzamine was added in a volume of 20 tA and the tissue was allowed to contact with the antagonists for 60 min prior to the initial challenge with Noradr.
Fici. 3. Effects of E-643, phentolamine and phenoxybenzamine on the contractile response of the isolated aortic strips to cumulative concentrations of noradrenaline. The ordinate indicates per cent of maximum contraction. The maximum attainable tension of each strip to cumulatively applied noradrenaline prior to the addition of an antagonist was taken as 100%. The abscissa represents molar concentration of noradrenaline. Molar concentration of antagonists are given on each curve. Each point denotes the mean standard error of six experiments except that on the control curves (denoted by `0') where the number of experiments was 18. Phenoxybenzamine, on the other hand, produced a progressive depression of the maximum tension. None of these antagonists produced a change in resting tension. Reversibility of the a-blocking effect : Since E-643 exhibited a long-lasting fall in blood pressure after an oral administration (1, 2), the possibility that E-643 may exert a long lasting hypotension through irreversible binding with the a-receptors had to be considered.
Therefore, recovery of the contractile response of the strip to Noradr was recorded at different times after washout.
Aortic strips were exposed to 10-6 M of Noradr which produced contractions approx. Noradr recovered rapidly in the aorta which had been treated with E-643 or phentolamine.
Complete recovery of the responsiveness was obtained after the third wash. On the other hand, recovery of the contractile response was slow in the aorta which had been treated with phenoxybenzamine.
Protection experiment:
The above results suggest that the nature of the a-blocking action of E-643 is comparable to that of a competitive and reversible a-blocker, phentol amine.
To procure direct evidence, a protection experiment was carried out, as described by Furchgott (5).
E-643 or phentolamine was added to the bath first, and one min later 10-7 M of phenoxy benzamine was added and the tissue was exposed to this drug for 15 min. Thereafter, the Effects on K+-, Bat+ and angiotensin-induced contractions: To determine whether E-643 has a direct effect on the aortic smooth muscle, interaction of E-643 with K+-, Baz+_ or angiotensin 11-induced contraction was investigated. A single submaximum concen tration of agonists, which produced 80% of the maximum contraction, i.e., 30 mM of KCI, 4 mM of BaC12 and 3 x 10-9 M of angiotensin 11 was selected. After obtaining a control contraction for each agonist, E-643, phentolamine or verapamil was added to the bath and the tissue was exposed to the drug for five min before the repeated addition of the agonists.
Results of these experiments are summarized in Table 1 The results are shown in These data suggest that E-643 may exert its hypotensive effect by blocking the action of noradrenaline at the receptor site rather than by acting directly on the smooth muscle.
Recent studies (7) (8) (9) suggested the existence of a-adrenoceptors at the presynaptic terminals of the sympathetic nerve. An increased concentration of noradrenaline in the synaptic cleft reduces the catecholamine release from the nerve terminals by a negative feedback mechanism and a-blockers which act on the presynaptic receptors block this regulation, resulting in marked enhancement of the amine release. In fact, phentolamine and other a-blockers were reported to block not only post but also presynaptic a-receptors (10, 11) .
Although, there is no direct evidence indicating that E-643 selectively blocks the post 
